Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra, Kay-Dietrich Wagner, Nicole Wagner · 2024
Read Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease by Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra, Kay-Dietrich Wagner, Nicole Wagner (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674254.txt.
Description
Ana Paula Madariaga Traconis and co-authors review, in a 2024 paper, how a family of hormone receptors links blood vessel health to fatty liver disease. The liver condition, called MASLD, often sits beside heart and vessel disease. A shared thread is endothelial dysfunction, where the vessel lining loses its balance and nitric oxide runs low. In the liver, that state wakes up cells that drive scarring.
The receptors, known as PPARs, help steer metabolism and inflammation across the gut, liver, and fat tissue. Drugs that switch them on are in wide testing. Several named agents have shown gains for liver, metabolic, and heart health in patients and lab studies. The review maps how these receptors act, how they may slow the disease, and where drug targeting looks most promising.
Catalog record
| CREATOR | Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra, Kay-Dietrich Wagner, Nicole Wagner |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |